Back to top
more

Avita Medical (RCEL)

(Delayed Data from NSDQ)

$10.30 USD

10.30
71,626

+0.20 (1.98%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $10.29 -0.01 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Avita (RCEL) Falls 19% on Lowered 2023 Revenue Guidance

by Zacks Equity Research

Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.

Strength Seen in Avita Medical Inc. (RCEL): Can Its 20.4% Jump Turn into More Strength?

by Zacks Equity Research

Avita Medical Inc. (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AVITA (RCEL) Gets FDA Nod for Expanded Use of RECELL System

by Zacks Equity Research

AVITA (RCEL) surges on FDA approval for expanded use of its RECELL System to treat full-thickness skin defects.

Here's Why Momentum in Avita Medical Inc. (RCEL) Should Keep going

by Zacks Equity Research

Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Indaptus (INDP) Surges on Upbeat Pre-Clinical Decoy Data

by Zacks Equity Research

Indaptus (INDP) announces positive pre-clinical efficacy data from a poster presentation made at a scientific conference from its proprietary Decoy platform pre-clinical study. Stock is up 22%.

What Makes Avita Medical Inc. (RCEL) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Novo Nordisk (NVO) Increases Sales & Operating Profit Guidance

by Zacks Equity Research

Novo Nordisk (NVO) increases annual guidance for the year 2023 on higher sales expectations for Ozempic and Wegovy.

Novo (NVO) & Aspect Biosystems Unite to Develop Tissue Therapy

by Zacks Equity Research

Pharma Goliath Novo Nordisk (NVO) inks collaboration agreement with Aspect Biosystems to develop and commercialize transformative cell therapy treatments for type I diabetes patients.

Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent

by Zacks Equity Research

Aurinia Pharmaceuticals (AUPH) announces the issue of its new and refined method-of-use patent, supplementing its existing patent, for Lupkynis to treat lupus nephritis. Shares are up 11%.

Here's What Could Help Avita Medical Inc. (RCEL) Maintain Its Recent Price Strength

by Zacks Equity Research

Avita Medical Inc. (RCEL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review

by Zacks Equity Research

The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks. A final decision is expected by November 2023.

Novo Nordisk (NVO) Meets Semaglutide Higher Dosage Study Goal

by Zacks Equity Research

Novo Nordisk (NVO) announces positive top-line results from its phase III increased dosage study of semaglutide, 25 mg and 50 mg, for the treatment of patients with type II diabetes.

89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study

by Zacks Equity Research

Data from a phase IIb study showed that treatment with 89bio's (ETNB) lead candidate improved fibrosis improved fibrosis at 3.5 times the rate of the placebo without worsening NASH.

BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why

by Zacks Equity Research

Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of dwarfism.

Altimmune (ALT) Stock Down Despite Positive Obesity Study Data

by Zacks Equity Research

Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate.

Karuna's (KRTX) KarXT Meets Primary Goal in Schizophrenia Study

by Zacks Equity Research

Data from a late-stage study shows that treatment with Karuna's (KRTX) lead candidate, KarXT, led to an early and sustained statistically significant reduction of symptoms of schizophrenia.

Esperion (ESPR) Plummets 54% Over Milestone Payment Row

by Zacks Equity Research

An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.

Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study

by Zacks Equity Research

Data from a mid-stage study showed that Merck's (MRK) MK-7684A did not improve progression-free survival as a potential treatment for patients with metastatic non-small cell lung cancer.

Catalyst's (CPRX) Q4 Earnings & Sales Top, Boosted by Firdapse

by Zacks Equity Research

Catalyst Pharmaceuticals (CPRX) reports better-than-expected financial performance as it beats both earnings and revenue estimates. Firdapse sales continue to grow year over year.

What Makes Avita Medical Inc. (RCEL) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

How Much Upside is Left in Avita Medical Inc. (RCEL)? Wall Street Analysts Think 27.42%

by Zacks Equity Research

The mean of analysts' price targets for Avita Medical Inc. (RCEL) points to a 27.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall

by Zacks Equity Research

Pacira BioSciences (PCRX) reports mixed fourth-quarter financial results, where earnings match estimates, but revenues miss the mark.

Here's Why 'Trend' Investors Would Love Betting on Avita Medical Inc. (RCEL)

by Zacks Equity Research

Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Avita Medical Inc. (RCEL) Stock Jumps 6.2%: Will It Continue to Soar?

by Zacks Equity Research

Avita Medical Inc. (RCEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts See a 127% Upside in Avita Medical Inc. (RCEL): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 127.1% in Avita Medical Inc. (RCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.